While Cologuard has long been productive, you can find concerns with Exact Sciences that investors won't be able to forget about. Initial, the corporation's prime-line progress fee continues to be decreasing. In the 1st quarter, Precise Sciences' revenue of $638 million enhanced by just under six% 12 months above calendar year.?????????????????????